Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant proportion of HER2-positive patients are either inherently resistant or develop resistance to trastuzumab. We assessed the effects of neratinib, an irreversible panHER inhibito...

Full description

Bibliographic Details
Main Authors: Canonici, Alexandra, Gijsen, Merel, Mullooly, Maeve, Bennett, Ruth, Bouguern, Noujoude, Pedersen, Kasper, O'Brien, Neil A, Roxanis, Ioannis, Li, Ji-Liang, Bridge, Esther, Finn, Richard, Slamon, Dennis, McGowan, Patricia, Duffy, Michael J., O'Donovan, Norma, Crown, John, Kong, Anthony
Format: Online
Language:English
Published: Impact Journals LLC 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858548/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858548/

Similar Items